Kidney International

Omeros Corporation Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, DSM-IV codes, Survival, Tardive dyskinesia, Bangladesh Technical Education Board, Data analysis, Patent, Investment, Patient, Congress, BLA, Inflammation, Emory University, Therapy, Paroxysmal nocturnal hemoglobinuria, European Hematology Association, Research, Emory, Government, Proteinuria, Kidney International, CUD, Glomerulus, Manuscript, L-DOPA, Hematuria, Safety, Omeros, COVID-19, Inflammation Research, Immunoglobulin A, Fibrosis, PIN, Cancer, PNH, National Institute on Drug Abuse, LID, PDE7, Hemolysis, Complement, Clinical trial, Mannan-binding lectin, Sale, Trial of the century, IgA nephropathy, Corporation, NIDA, Society, C5, Pharmaceutical industry, Reinsurance, Music, Security (finance), Vaccine, Video game, Frontiers, Hematology, Immunology, Agency

“Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Key Points: 
  • “Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.
  • Total costs and expenses for the second quarter of 2023 were $40.9 million compared to $37.4 million for the second quarter of 2022.
  • Interest expense during the second quarter of 2023 was $7.9 million compared to $4.9 million during the prior year quarter.
  • During the second quarter of 2023, we earned $4.5 million in interest and other income compared to $0.7 million in the prior year quarter.

Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, May 17, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Adrenoleukodystrophy, Prescription, Imeglimin, Adenosine, Plasma, Journal, JPY, Patient, Serono, Merck, POC, Sumitomo Group, Disease, Male, Business development, FY, Pharmacokinetics, Autosomal dominant polycystic kidney disease, American Association for the Study of Liver Diseases, USD, European Commission, Polycystic kidney disease, Kidney International, HIV disease progression rates, Fatty liver disease, ADPKD, FDA, IPF, Safety, Abstract, DPP4, ALD, ODD, JDS, Merck Serono, Biomarker, DSM-IV codes, AMN, Non-U.S. operators of the M60 Patton, IRIS, Sumitomo Pharma, SGLT2, VLCFA, Life Sciences (journal), Regulation of tobacco by the U.S. Food and Drug Administration, Food, Autosome, Pharmaceutical industry, Bank, Management, EUR, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2023.
  • Thomas Kuhn, Chief Executive Officer of Poxel, stated: “This quarter we successfully restructured our debt obligations and increased our financial flexibility with a new equity-linked financing with IRIS.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • As of March 31, 2023, cash and cash equivalents were EUR 10.6 million (USD 11.6 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update

Retrieved on: 
Thursday, March 23, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Journal of Hepatology, Prescription, Imeglimin, Adenosine, Plasma, Journal, Magnetic resonance imaging, JPY, Patient, Serono, Histology, Conditional sentence, Merck, POC, Pioglitazone, Sumitomo Group, Disease, Male, Pharmacokinetics, Autosomal dominant polycystic kidney disease, European Commission, Kidney International, HIV disease progression rates, Fatty liver disease, ADPKD, FDA, IPF, Safety, ALD, ODD, Merck Serono, Medicine, Biomarker, DSM-IV codes, Fibrosis, Human, Adrenoleukodystrophy, Acceleration, AMN, Workforce, Partnership, IRIS, Sumitomo Pharma, Edema, Clinical trial, VLCFA, EUR, Life Sciences (journal), Regulation of tobacco by the U.S. Food and Drug Administration, Food, TZD, Pharmaceutical industry, Management, Security (finance), Euronext

POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its results for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516) (Paris:POXEL), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its results for the year ended December 31, 2022 and provided a corporate update.
  • Based on recent sales trends, Sumitomo has increased its fiscal year 20223 forecast by 20% to JPY 1.8 billion6 (EUR 12.8 million)5.
  • For the Sumitomo fiscal year 2023 (ending March 31, 2024), as a conservative assumption, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • Beyond 2024, Poxel expects to receive escalating double-digit royalties as well as additional sales-based payments upon achievement of contractually based sales thresholds.

Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Wednesday, March 1, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Kidney International, MD, ADPKD, Disease, AMPK, DSM-IV codes, Fatty liver disease, Adenosine, Kidney, Life Sciences (journal), Autosomal dominant polycystic kidney disease, NASH, HIV disease progression rates, Conditional sentence, Euronext, Tolvaptan, Pharmaceutical industry

POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator.

Key Points: 
  • POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator.
  • To access the publication online in the life sciences journal, Kidney International, please use the following link: A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease.
  • (kidney-international.org)
    “ADPKD remains a major cause of end stage renal disease and is associated with substantial additional unmet medical needs.
  • These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in a Phase 2 clinical program for ADPKD.”

CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week

Retrieved on: 
Wednesday, November 2, 2022
Health, Surgery, Genetics, Clinical Trials, Research, Science, Biotechnology, MPH, Annual report, DNA, Allotransplantation, CEO, Health, SEC, Time, Kidney International, Society, Nasdaq, American Society of Nephrology, ASN, Transplant, Associate, Patient, Precision medicine, 2021 Essex County Council election, De novo, Solution, Caregiver, Pharmaceutical industry, Dentistry, MD, Nephrology, Kidney

At ASN Kidney Week, CareDx is featured in nine abstracts and posters, and one oral presentation, several of which add to the clinical utility data showing AlloSure as an important surveillance tool for transplant patient management. These latest presentations are consistent with the findings of the landmark 2021 ADMIRAL study1 -- the industry’s first long-term, 3-year, multicenter prospective clinical validation for routine kidney transplant surveillance. The study showed that AlloSure provides an early and accurate assessment of allograft injury when used in routine kidney transplant surveillance and can predict long-term graft survival outcomes. AlloSureis the first donor-derived cell-free DNA (dd-cfDNA) solution to demonstrate clinical utility in prediction of de novo donor-specific antibody, and both subclinical and clinical rejection in a long-term study.1

Key Points: 
  • ASN Kidney Week is an excellent opportunity for CareDx to expand further into transplant nephrology in the community setting, where we will be sharing the latest AlloSure Kidney data and digital solutions to help nephrologists manage the complexities of transplant patient care, said Reg Seeto, CEO and President of CareDx.
  • At ASN Kidney Week, CareDx is featured in nine abstracts and posters, and one oral presentation, several of which add to the clinical utility data showing AlloSure as an important surveillance tool for transplant patient management.
  • CareDx is a provider of digital health solutions that powerfully link participating transplant centers, healthcare providers, and patients in better navigating the complex transplant journey to improve patient care.
  • During ASN Kidney Week CareDx will be onsite to highlight how its digital health solutions support clinical practice and help centers achieve operational efficiency.

CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk

Retrieved on: 
Thursday, June 2, 2022
Medical Devices, Health, Surgery, Pharmaceutical, Cardiology, Biotechnology, Online, Biomarker, Prognosis, Caregiver, Congress, Precision medicine, Kidney transplantation, PMID, Doctor of Philosophy, Survival, Dave's Picks Volume 37, Validation, Dean Hart, Medical director, Kidney failure, Population, Pancreas transplantation, FC, Cardiac allograft vasculopathy, ATC, Artificial intelligence, DOI, Veni, vidi, vici, CLIA, CEO, Partnership, ET, Solution, Immunosuppression, Illusion of validity, Annual report, University, Physician, Long-term care, CAV, Patient, DNA, Gene expression, SEC, University of Utah, Nasdaq, Utility, Risk, Kidney International, Y Touring Theatre Company, Death, Dentistry, Medical device, Pharmaceutical industry, Entertainment, Silviculture, Sex industry, Transplant, Kidney, MD, Medicine

This follows CareDxs recently announced plans to add an artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV).

Key Points: 
  • This follows CareDxs recently announced plans to add an artificial intelligence (AI) prognostic for cardiac allograft vasculopathy (CAV).
  • AiKidney can be used for informing clinical management decisions and to help clinicians predict the long-term impact of treatments.
  • This ongoing partnership is yielding positive results and it is exciting to see AiKidney coming to fruition in the clinic.
  • AiKidney supports this assessment by providing information about a patients risk of allograft rejection and expected long-term graft survival.

OmniLife Named Winner of the 2022 Lyfebulb-CVS Kidney Care® Innovation Challenge

Retrieved on: 
Friday, May 20, 2022
Entrepreneurship, Chronic kidney disease, CVS Health, CKD, Fireside chats, Health equity, ESRD, Kindness, Patient, Health, Solution, LAUNCH (Innovation Challenge), EST, Kidney, Kidney disease, Awareness, NYSE, Estadio Akron, Instagram, Communication, Conditional sentence, Kidney International, LinkedIn, Twitter, Founder, MD, Fireside, CEO, Pharmaceutical industry, Medicine, Health insurance, Facebook

NEW YORK and WOONSOCKET, R.I., May 20, 2022 /PRNewswire/ -- Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and CVS Kidney Care®, a CVS Health® (NYSE: CVS) company, are excited to announce that OmniLife was selected as the winner, and Kindness for Kidneys International received an honorable mention, at the 2022 Lyfebulb–CVS Kidney Care® Innovation Challenge: Accelerating Innovations in Kidney Disease to Improve Health Equity and Outcomes.

Key Points: 
  • "True equity means everyone has the opportunity to attain their full health potential," said Jesse Roach, MD, Senior Medical Director, Health Equity at CVS Kidney Care.
  • "We applaud OmniLife, Kindness for Kidneys and the other challenge finalists for their efforts to addressbarriers to care that make preventingandmanaging kidney disease difficult."
  • The 2022 Innovation Challenge took place in Austin, TX over two days on May 18-19.
  • We are changing kidney care as we know it because the more than 37 million Americans living with chronic kidney disease deserve more than twentieth-century solutions.

How Fresenius Medical Care’s Superhero Is Helping Bridge the Knowledge Gap to Better Kidney Health

Retrieved on: 
Thursday, March 10, 2022
Social Media, Online, Mobile Entertainment, Pharmaceutical, Communications, General Health, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, Entertainment, Other Science, Health, Research, People, Kidney International, Frankfurt Stock Exchange, Partnership, Public health, Instagram, Experiment, Animation, FMS, Adoption, FME, United States Department of Health and Human Services, Kidney, Fresenius Medical Care, EMEA, Program, Literacy, Health care, Corporate social responsibility, Dialysis, World Kidney Day, Boy, Journal of Medical Internet Research, Health literacy, Facebook, Parent, Patient, Marketing, Organization, CEO, Awareness, Review, Medicine, Kidney disease, Literature, Research, Prevalence, New, Forbes, Knowledge, Systematic review, CSR, Effectiveness, School, Profile, Education, App store, Social media, Human services, Pharmaceutical industry, Toy, Medical device

The initiatives latest development comes on World Kidney Day 2022, which is urging the community, healthcare workers, and public health policymakers to Bridge the knowledge gap to better kidney care which aligns precisely with The Kidney Kids mission.

Key Points: 
  • The initiatives latest development comes on World Kidney Day 2022, which is urging the community, healthcare workers, and public health policymakers to Bridge the knowledge gap to better kidney care which aligns precisely with The Kidney Kids mission.
  • View the full release here: https://www.businesswire.com/news/home/20220310005537/en/
    Fresenius Medical Cares superhero, The Kidney Kid, contributes to bridging the knowledge gap to better kidney health by helping children learn more about their super organ kidneys and how to keep them healthy.
  • Fresenius Medical Cares worldwide community is creating further opportunities to foster the exchange of kidney health knowledge between individuals, communities and healthcare professionals.
  • Indeed, it was recognition of this gap that led to Fresenius Medical Care creating The Kidney Kid from as early as 2014.

Fresenius Medical Care Unveils Intelligent Home Dialysis Solutions at China International Import Expo (CIIE)

Retrieved on: 
Wednesday, November 10, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Managed Care, General Health, Health, People, Fresenius Medical Care, Quality of life, Peritoneal cavity, HD, Efficiency, Meta-analysis, Dialysis, CAPD, Abdomen, PD, Critical care, U.S. Securities and Exchange Commission, CEO, Peritoneal dialysis, Frankfurt Stock Exchange, Waste, Lea, Water, Blood, Â, New, FMS, COVID-19, Multimedia, Research, Nephrology, Kidney, Chronic kidney disease, Data analysis, APD, China International Import Expo, Solution, Systematic review, Hope, Prevalence, Oke, Patient, Employment, FME, Kidney International, Health care, Medical device, Health insurance, Pharmaceutical industry

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today presented its advances in home dialysis solutions at the China International Import Expo (CIIE) in Shanghai.

Key Points: 
  • Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today presented its advances in home dialysis solutions at the China International Import Expo (CIIE) in Shanghai.
  • View the full release here: https://www.businesswire.com/news/home/20211109006717/en/
    Fresenius Medical Care unveils its intelligent home dialysis solutions at the China International Import Expo.
  • Mr. Alan Chen, Executive Vice President of Fresenius Medical Care Greater China, said, This is the third time that Fresenius Medical Care has participated at CIIE.
  • Through its network of 4,151 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 345,000 patients around the globe.